In the face of controversies around the quality of medicines manufactured by some Indian pharma companies in domestic and foreign markets, as well as GoI's invitation to stakeholders to make suggestions for the draft New Drugs, Medical Devices and Cosmetics (D&C) Bill, 2022 - updating the Drugs and Cosmetics Act (DCA), 1940 - this conversation is welcome.
